BackgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent chronic inflammatory condition affecting the nose and paranasal sinuses, posing a significant socio‐economic impact with substantial challenges in management. Biologics targeting type 2 inflammation such as dupilumab, have emerged as promising options. This study addresses a critical knowledge gap by comprehensively evaluating the 3‐year impact of sustained dupilumab therapy in CRSwNP.MethodsA multicentric, retrospective collection of real‐world data from five tertiary referral centers in Germany was conducted, enrolling 150 adult patients. The study investigated patient‐reported outcomes, disease‐specific indices and clinical measures, focusing on therapeutic response persistence, adverse events, and factors influencing treatment continuity.ResultsResults indicate significant improvements in clinical parameters from baseline (n = 150) with sustained effectiveness after 36 months (n = 138) as indicated in mean score ± standard deviation. Dupilumab treatment significantly improved overall disease‐related impairment (VAS score: 7.5 ± 2.5 to 1.6 ± 1.3) and rhinosinusitis symptoms (SNOT‐22: 59.4 ± 19.4 to 18.0 ± 15.0). Nasal Polyp Scores (NPS) decreased (5.3 ± 1.8 to 0.7 ± 1.1), and olfactory function improved (3.2 ± 2.5 to 8.4 ± 2.8), with three out of four patients achieving normosmia or hyposmia after 36 months. An “Excellent” treatment response according to EUFOREA23 criteria was observed in 76.5% of patients after 36 months. Sixteen patients discontinued Dupilumab, 12 permanently. Adverse events totaled 69 in 48 patients, commonly self‐limiting.ConclusionThe study highlights the enduring effectiveness and lack of habituation to dupilumab after a sustained therapy of 3 years, providing valuable insights into its long‐term therapeutic implications for CRSwNP patients.

中文翻译：

---

真实世界数据显示 dupilumab 对慢性鼻窦炎伴鼻息肉 (CRSwNP) 的持续治疗效果超过 3 年


背景慢性鼻窦炎伴鼻息肉（CRSwNP）是一种影响鼻子和鼻旁窦的常见慢性炎症性疾病，造成重大的社会经济影响，给治疗带来巨大挑战。针对 2 型炎症的生物制剂（例如 dupilumab）已成为有前景的选择。这项研究通过全面评估持续 dupilumab 治疗对 CRSwNP 的 3 年影响，解决了一个关键的知识差距。方法对来自德国五个三级转诊中心的真实世界数据进行了多中心、回顾性收集，招募了 150 名成年患者。该研究调查了患者报告的结果、疾病特异性指标和临床测量，重点关注治疗反应持续性、不良事件和影响治疗连续性的因素。结果结果表明临床参数较基线有显着改善（ n = 150) 36 个月后持续有效 ( n = 138)，以平均分±标准差表示。 Dupilumab 治疗显着改善了总体疾病相关损伤（VAS 评分：7.5 ± 2.5 至 1.6 ± 1.3）和鼻窦炎症状（SNOT-22：59.4 ± 19.4 至 18.0 ± 15.0）。鼻息肉评分 (NPS) 下降（5.3 ± 1.8 至 0.7 ± 1.1），嗅觉功能改善（3.2 ± 2.5 至 8.4 ± 2.8），四分之三的患者在 36 个月后达到嗅觉正常或嗅觉减退。 36 个月后，76.5% 的患者出现了根据 EUFOREA23 标准的“优秀”治疗反应。 16 名患者停用 Dupilumab，其中 12 名永久停用。 48 名患者共出现 69 起不良事件，且通常具有自限性。结论该研究强调了 dupilumab 在持续治疗 3 年后的持久有效性和缺乏习惯性，为了解其对 CRSwNP 患者的长期治疗影响提供了宝贵的见解。